Sutton D G M, Preston T, Christley R M, Cohen N D, Love S, Roussel A J
Institute of Comparative Medicine, University of Glasgow Veterinary School, UK.
Equine Vet J. 2002 Jul;34(5):486-92. doi: 10.2746/042516402776117818.
The aim of this study was to measure the effects of specific commonly used sedative protocols on equine solid phase gastric emptying rate, using the 13C-octanoic acid breath test (13C-OABT). The gastric emptying of a standard 13C-labelled test meal was measured once weekly in 8 mature horses over two 4 week treatment periods. Each horse acted as its own control. In treatment Period 1, saline (2 ml i.v.), xylazine (0.5 mg/kg i.v.), detomidine (0.01 mg/kg i.v.) or detomidine/butorphanol combination (0.01/0.02 mg/kg i.v.) was administered in randomised order after ingestion of the test meal. During treatment Period 2, test meal consumption was followed by saline, xylazine (1.0 mg/kg i.v.), or detomidine (0.03 mg/kg i.v.) administration, or preceded by acepromazine (0.05 mg/kg i.m.) in randomised order. The 13C:12C ratio of sequential expiratory breath samples was determined by isotope ratio mass spectrometry, and used to measure the gastric half-emptying time, t 1/2, and duration of the lag phase, t lag, for each of the 64 tests. In treatment Period 1, detomidine/butorphanol prolonged both t 1/2 and t lag with respect to xylazine 0.5 mg/kg and the saline control (P < 0.05). In Period 2, detomidine 0.03 mg/kg delayed each parameter with respect to saline, acepromazine and xylazine 1.0 mg/kg (P < 0.001). Xylazine 1.0 mg/kg also lengthened t lag relative to the saline control (P = 0.0004), but did not cause a significant change in t 1/2. Comparison of treatment periods showed that the inhibitory effect of detomidine on gastric emptying rate was dose related (P<0.05). These findings may have clinical significance for case selection when these agents are used for purposes of sedation and/or analgesia.
本研究的目的是使用13C-辛酸呼气试验(13C-OABT)来测定特定常用镇静方案对马固相胃排空率的影响。在两个为期4周的治疗期内,每周对8匹成年马的标准13C标记测试餐的胃排空情况进行一次测量。每匹马都作为自身对照。在治疗期1,在摄入测试餐后,以随机顺序静脉注射生理盐水(2 ml)、赛拉嗪(0.5 mg/kg静脉注射)、右美托咪定(0.01 mg/kg静脉注射)或右美托咪定/布托啡诺组合(0.01/0.02 mg/kg静脉注射)。在治疗期2,在摄入测试餐后,以随机顺序静脉注射生理盐水、赛拉嗪(1.0 mg/kg静脉注射)或右美托咪定(0.03 mg/kg静脉注射),或者在摄入测试餐前肌肉注射乙酰丙嗪(0.05 mg/kg)。通过同位素比率质谱法测定连续呼气样本的13C:12C比率,并用于测量64次测试中每次测试的胃半排空时间t1/2和延迟期持续时间tlag。在治疗期1,相对于0.5 mg/kg赛拉嗪和生理盐水对照,右美托咪定/布托啡诺延长了t1/2和tlag(P < 0.05)。在治疗期2,相对于生理盐水、乙酰丙嗪和1.0 mg/kg赛拉嗪,0.03 mg/kg右美托咪定延迟了每个参数(P < 0.001)。1.0 mg/kg赛拉嗪相对于生理盐水对照也延长了tlag(P = 0.0004),但未导致t1/2发生显著变化。治疗期比较显示,右美托咪定对胃排空率的抑制作用与剂量相关(P<0.05)。当这些药物用于镇静和/或镇痛目的时,这些发现可能对病例选择具有临床意义。